Company intelligence / Profile preview
Grifols
- Ownership
- Public · GRFS
- Employees
- ~23800
- Development stage
- Other
Overview
Grifols markets multiple commercialized plasma-derived therapies globally. Its products are standard of care in several rare/chronic diseases with ongoing R&D into new plasma-based therapeutics and recombinant antibody drugs. The company operates the world’s largest network of plasma donation centers to support its manufacturing scale.[1][3][5]
- Therapeutic areas
- GastroenterologyPulmonologyImmunologyHematologyNeurologyInfectious Diseases
- Modalities
- Plasma-derived biologics (immunoglobulins, albumin, clotting factors)Recombinant antibody drugs (in development)[4]Diagnostic technologies[2][3]
- Industry
- Biotech
Drug pipeline
28 assets27 more assets in the full pipeline.
Partnerships
Financials
- Market cap
- $7.2B
- Total revenue
- $8.1B
- Enterprise value
- $16.9B
Beyond the preview
Go deeper on Grifols.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Grifols.